Duloxetine is NOT a first-line agent for migraine prevention and lacks robust evidence for this indication
Based on established migraine prevention guidelines, duloxetine should not be used as a primary migraine preventive medication. The most recent and authoritative guidelines clearly identify first-line agents for migraine prevention, and duloxetine is notably absent from these recommendations.
Evidence-Based First-Line Agents for Migraine Prevention
According to the 2025 American College of Physicians guideline 1 and the 2024 VA/DoD guideline 2, the established first-line preventive agents for episodic migraine include:
- Beta-blockers: Propranolol (80-240 mg/d) and timolol (20-30 mg/d) 3
- Tricyclic antidepressants: Amitriptyline (30-150 mg/d) 3
- Antiseizure medications: Divalproex sodium (500-1500 mg/d) and topiramate 3, 2
- CGRP antagonists: Erenumab, fremanezumab, galcanezumab (strong recommendation) 2
Why Duloxetine Is Not Recommended
Duloxetine has not been studied specifically for migraine prevention 4. The evidence cited for duloxetine pertains exclusively to neuropathic pain conditions (diabetic peripheral neuropathy), not migraine 4. The available research on duloxetine for migraine consists only of:
- Small retrospective case series showing minimal effectiveness (22% responder rate) 5
- One non-English language study in chronic migraine 6
- Recent observational data suggesting higher rates of psychiatric adverse outcomes compared to amitriptyline 7
A comprehensive review concluded that duloxetine demonstrates "minimal effectiveness as a headache preventive medication" 5.
Clinical Considerations with Concurrent Buspirone
Regarding the patient's current buspirone therapy for anxiety:
There are no significant drug interactions between duloxetine and buspirone based on FDA labeling 8. Buspirone's interactions primarily involve CYP3A4 inhibitors/inducers, while duloxetine affects CYP1A2 and CYP2D6 8.
Interestingly, buspirone itself has shown some evidence for migraine prevention in patients with comorbid anxiety (43% reduction in headache frequency) 9, 10, though this evidence is limited to small trials.
Recommended Approach
For this patient with migraines and anxiety:
- First choice: Amitriptyline 30-150 mg/d 3 - addresses both migraine prevention and anxiety, with superior evidence compared to duloxetine for both conditions
- Alternative if amitriptyline not tolerated: Propranolol 80-240 mg/d 3 - also beneficial for anxiety
- Continue buspirone for anxiety management, as it may provide additional migraine benefit 9, 10
If the patient meets criteria for preventive therapy (≥2 attacks/month producing ≥3 days disability, or use of abortive medication >2×/week) 3, 11, initiate with low doses and titrate slowly over 2-3 months for adequate trial 3.
Common Pitfalls to Avoid
- Do not use duloxetine based solely on its antidepressant properties or comorbid anxiety—the evidence for migraine prevention is insufficient
- Do not assume SNRIs as a class are equivalent to TCAs for migraine—only amitriptyline has robust evidence 12
- Ensure acute migraine treatment is optimized with NSAIDs or triptans before adding preventive therapy 3, 11